Clarification Post.... Reading my previous post where I

New Post Public Reply Private Reply Replies (1) Message Board
joey68 joey68 #859
Clarification Post....

Reading my previous post where I said, "ultimately, a buyout is the only option", I didn't mean that in a negative way. Read all my old DD and youll see why I think this.

SCIE management's average age is in their upper 60's at least. These guys are seasoned professionals. More than likely, Oliver doesn't want to sit at a desk in his retirement days. He wants to bask in the sunshine knowing that he turned a crap company into a multi-million dollar business by selling it to a mega company.

Remember, way before Oliver came on the scene, SCIE was a complete mess.

My post from August 2016:

Quote:
The company has been around for a very long time but the majority of the previous years were a mess. They were working on a LUMA device which doesnt even exist anymore, management was a mess.. Oliver became the CEO only a few short years ago...the list goes on and on. Oliver even admitted in a video that SCIE lost over a year trying to penetrate the UK on their own.


(The video is posted in one of my old posts)

In my opinion, believing that a buyout is the ultimate goal makes it much simpler to invest in SCIE.

My post from April 2016:

Quote:
I'm not in love with Spectrascience. I see their technology filling a global need, and this will make me a profit.


This is what is important to me. There are pennystocks out there trying to sell pancake batter. Could it succeed? Sure it could. Is there a global need for it. No. There is a global need for better cancer detection technology. SCIE has a working device which does just that.

Remember the last 10Q? "Over $4 million are in default owned by 79 investors."

That's what makes me believe in this company. These 79 people are real individuals. They could easily give up on SCIE and demand their money back; but they don't. Its my belief these investors know SCIE has a very good chance of succeeding and are allowing them time to do their stuff.

This post isn't me telling anyone to "stick it out with SCIE" or "buy on the dips". Everyone needs to do what they feel is best for themselves. This post is me stating my opinion.

Could SCIE fail miserably? Sure it could. Its a stock. Will it? I don't think it will. Investors are extremely dramatic, fickle people who will love their positions one day and despise them the next; only to re-love them the very next day once a PR comes out. But investing based on emotion alone almost always equates to loss.

SCIE is current. We haven't received any bad PRs.

Medtech is in January.

The MORDIS trial is still current.

Quote:
ClinicalTrials.gov processed this record on December 06, 2016


https://clinicaltrials.gov/ct2/show/NCT01980134

Some of the top people in the field are investigating the WavSTAT.

Does all of this information 'insist' investors remain invested in SCIE? Of course not. We can all sell just as easily as we can buy. Ive said it many times - Being 'long' in a stock doesn't have to mean holding forever. Sell if you think its good to sell, and then jump back in when the price is lower. Heck, I'm long in many stocks that I'm not invested in.

That's the issue with online investing and these crazy investment boards. We constantly read people saying "Buy on the dips!", "Hold!", "Gift prices!", "I'm long forever!"....

Long forever? What does that even mean? Like BLTA? A stock which, two years ago, I shared my opinion in these boards that it was time to sell; sold at the high; mocked by BLTA investors that I made the 'wrong decision' (even now if I try to post, my posts are automatically deleted because they aren't 'feel good pro-BLTA centered).. and yet its been downhill ever since. A stock that's pretty much dead, yet investors insist its going to somehow magically succeed. A stock that investors know in their gut will probably never make their money back, yet they insist on not selling at a loss. But hey, to each their own; maybe BLTA will skyrocket in price..........

ive made a number of poor investment decisions in my life as well, and investing is a learning experience.

But that's the main point of this ridiculously, drawn out post. Investing is about LEARNING. If we constantly find ourselves never selling on time before the price crashes, we have two choices:

1. Keep doing the same thing
or
2. Learn why it keeps happening, adjust your investment strategies, and continue on.

Has anyone besides myself noticed there is not a shred of DD going on in the SCIE boards anymore? Why not? I'm sure theres something new out there.

Remember China Forum VI in January 2016?
http://www.omcconference.com/

The requirements for this program is:

•FDA or CE approved products
•Breakthroughs nearing commercialization
•No current exclusive Chinese representation

Doesn't SCIE fall under those categories? Although this is pure guesswork, is it possible SCIE is working with companies in China?

On the webpage, it states:

Quote:

663 A medical device company that offers a simplified yet highly effective way of diagnosing colorectal cancer early, when recovery rates are highest. Their WavSTAT Optical Biopsy System ® uses light to determine tissue health, and instantly detects if tissue is normal, pre-cancerous or cancerous without the need for a costly physical biopsy


Which means SCIE is doing something, was doing something, or is trying to do something with China.

Is it possible there will be a China Forum VII in early 2017? Time will tell.

Do NOT invest based on this post. Although I don't post here much, its not because I don't believe in the company. Its because I don't have to convince myself anymore.

I stand by my saying of Do not invest more than you can afford to lose.
Not investment advice

SpectraSCIENCE Inc. (SCIE) Stock Research Links

SCIE Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 8

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 4

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 5

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 4

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 6

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 4

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading

Top 5 Most Recently Viewed Articles

Gentherm's Q2 2025 Results Highlight Strong Performance & Future

Updated Category News Views 132

Gentherm's Financial Performance for Second Quarter 2025 Gentherm, a global innovator in thermal management technologies, reported outstanding financial outcomes for the second quarter of 2025. The company's revenue reached $375 million, underscoring its strength in the automotive sector, particularly within Climate and Comfort Solutions. Record Achievements and New...

Continue Reading
DEALMining Surpasses 6.8 Million Users with Exciting Rewards

Updated Category News Views 237

DEALMining Achieves Major User Milestone In a significant accomplishment, DEALMining has proudly announced that its user base has exceeded 6.8 million globally, marking its status as one of the fastest-growing compliant cloud mining platforms in the world. This impressive growth showcases DEALMining's successful outreach across more than 200 countries and regions, as the...

Continue Reading
Investigation Launched into Aehr Test Systems for Investors' Losses

Updated Category News Views 218

Investigation into Aehr Test Systems, Inc. Focused on Investor Protection The Law Offices of Frank R. Cruz are actively investigating Aehr Test Systems, Inc. (NASDAQ: AEHR) in light of significant concerns raised regarding the company’s adherence to federal securities laws. This investigation comes as a response to alarming financial disclosures made public by the...

Continue Reading
Vivoryon Therapeutics to Share Insights on 2024 Performance

Updated Category News Views 176

Vivoryon Therapeutics N.V. Set to Report Financial Outcomes Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) is gearing up to unveil its financial results for the entirety of 2024, along with insights into its operational achievements. The highly anticipated announcement is scheduled for April 29, 2025, aiming to shed light on the company’s progress in...

Continue Reading
Navigating Economic Trends: Insights for Savvy Investors

Updated Category News Views 110

Understanding the Economic Climate In finance, a stable economy is often described as a "Goldilocks" economy, where conditions are ideal for investments to flourish. Lately, we have witnessed an economy that consistently surpasses expectations, putting worries about downturns to rest. The Search for Economic Balance Investors are keen to find that sweet spot where...

Continue Reading